Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin
2017
Online
unknown
Zugriff:
Objective To evaluate the reduction of thrombotic events (TE) in patients with essential thrombocythaemia (ET) treated with anagrelide versus hydroxyurea + aspirin (HU+ASA). Methods A questionnaire was developed using 2008 WHO diagnostic criteria, and thrombotic risk factors were stratified according to Landolfi criteria. Through questionnaire completion, clinicians at Hungarian haematological centres entered data into the Hungarian MPN Registry on patients with myeloproliferative neoplasms. Based on ET registry data, TEs in anagrelide-treated patients (n=139) were compared with HU+ASA-treated patients (n=141). Results Patients were followed up for (median) 6 years. TEs were reported in significantly fewer anagrelide-treated patients versus HU+ASA (15.1% versus 49.6%; p
Titel: |
Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin
|
---|---|
Autor/in / Beteiligte Person: | Egyed, Miklos ; Demeter, Judit ; Karádi, Éva ; Homor, Lajos ; Dombi, Péter ; Illés, Árpád ; Simon, Zsófia ; Udvardy, Miklós |
Link: | |
Veröffentlichung: | 2017 |
Medientyp: | unknown |
Schlagwort: |
|
Sonstiges: |
|